中医药联合EGFR-TKI治疗非小细胞肺癌的研究进展

肺癌是我国高发恶性肿瘤之一,以吉非替尼和厄洛替尼为代表的表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)已成为当今研究热点,但在其临床获益的同时伴随着不可避免的不良反应,中医药以其在肿瘤治疗中突出的增效减毒优势倍受关注。越来越多的学者致力于研究中医药联合EGFR-TKI治疗非小细胞肺癌。参考文献20篇。

Research Progress on the Therapy of Non-Small Cell Lung Cancer with Traditional Chinese Medicine Combined with EGFR-TKI

Lung cancer is a cancer of high occurrence in China. EGFR- TKI,such as gefitinib and erlotinib,has become a hotspot. Its clinical benefit,however,is always accompanied with unavoidable adverse reactions.Traditional Chinese medicine with its outstanding advantages in the treatment of tumors,which could reduce toxicity and enhance effect,has been highly regarded. More and more scholars are working on treatment of non- small cell lung cancer with traditional Chinese medicine combined EGFR- TKI. Its references include 20 research papers.